Methuselah Fund

The CEO, who also founded the Methuselah Foundation, and the Managing Director lead the investment process, supported by a deep bench of executive and scientific advisors from the longevity field. Specific deal-level authority is not publicly detailed. The firm's website does not name its leadership beyond their functional roles — CEO and Managing Director — omitting individuals' full names.

Deal flow comes almost entirely through the network of the Methuselah Foundation, a nonprofit the CEO launched 16 years prior to the Fund. The Foundation's scientific collaborators and its defined longevity strategies drive proprietary access to early-stage biopharma and biotech startups. This shared-origin structure means the Fund sees companies before typical venture firms, often at the translational stage.

It is structured as a private equity asset manager, not a single family office. Functionally, it operates as a mission-first venture fund tightly coupled to the Methuselah Foundation. All investments are direct equity stakes in for-profit longevity companies, with the stated priority of extending healthy human lifespan over pure financial return.

All disclosed portfolio activity is direct investments into operating companies. The firm shows no public history of fund-of-funds commitments or LP positions in external venture capital vehicles. Its capital structure as a private equity manager suggests it deploys directly into its seven-pillar longevity framework.

The portfolio spans pre-clinical to late-stage clinical biotech. Holdings include Leucadia Therapeutics, which is developing an Alzheimer's surgical procedure, OncoSenX, a late-stage pre-clinical cancer company, and others moving toward human data. The firm invests across the continuum where the underlying biology is mature enough for translation into a therapeutic or device.

Methuselah Fund is the for-profit venture arm of the Methuselah Foundation, a longevity-science nonprofit active for 16 years. The CEO runs both entities. The Fund invests in companies whose science often originates in the Foundation's ecosystem, creating a capital pipeline from foundational research to clinical development.

The firm's website does not state a co-investment policy. Given its embedded relationship with the Methuselah Foundation and the early-stage nature of its deals, the Fund may act as a first institutional check in some companies, but the extent of syndication with external VCs is not publicly confirmed.